Soleno Therapeutics, Inc. (NASDAQ:SLNO) is highlighted as one of the best healthcare stocks with the highest upside. Goldman Sachs initiated coverage with a Buy rating and $125 price target on October 7. The firm expects Soleno Therapeutics, Inc.’s Vykat XR to be a foundational treatment for Prader-Willi syndrome, potentially leading to a blockbuster franchise. Soleno Therapeutics, Inc. focuses on developing and commercializing novel therapeutics for rare diseases, with a lead candidate, Diazoxide Choline Controlled-Release (DCCR), targeting Prader-Willi Syndrome. While SLNO shows investment potential, some AI stocks may offer greater upside with less downside risk.

Read more at Yahoo Finance: Goldman Sachs Initiates Coverage of Soleno Therapeutics (SLNO) With a Buy Rating